SPY759.06+0.26%QQQ690.90+0.40%BTC/USD70,229.85−1.60%DIA523.24+0.15%GLD355.86+0.27%TLT79.57−0.19%

Teva Pharmaceutical Industries Ltd

TEVANYSE

Trade with Public

$43.65

0.410.95%

Last update: Nov 12, 7:42 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Teva Pharmaceutical Indus (TEVA) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Teva Pharmaceutical Indus (TEVA) stock.

Analyst Consensus — 13 Analysts

10Buy

3Hold

# Analysts13

Latest Upgrades and Downgrades for Teva Pharmaceutical Indus Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Piper Sandler	David Amsellem	PT Raise	Overweight	$44→$56
—	Leerink Partners	Daniel Clark	PT Raise	Outperform	$45→$52
—	TD Cowen	Joseph Thome	PT Raise	Buy	$55→$57
—	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$52→$54
—	HC Wainwright & Co.	Douglas Tsao	Initiate	Buy	$52
—	Barclays	Glen Santangelo	PT Raise	Overweight	$42→$47
—	JP Morgan	Chris Schott	PT Raise	Overweight	$40→$50
—	TD Cowen	Joseph Thome	Initiate	Buy	$55
—	Oppenheimer	Les Sulewski	Initiate	Outperform	$50
—	Leerink Partners	Daniel Clark	Initiate	Outperform	$45
—	UBS	Ashwani Verma	PT Raise	Buy	$42→$48
—	Barclays	Glen Santangelo	PT Raise	Overweight	$40→$42
—	Piper Sandler	David Amsellem	PT Raise	Overweight	$42→$44
—	Barclays	Glen Santangelo	PT Raise	Overweight	$38→$40
—	Truist Securities	Les Sulewski	PT Raise	Buy	$42→$45
—	Piper Sandler	David Amsellem	PT Raise	Overweight	$41→$42
—	UBS	Ashwani Verma	PT Raise	Buy	$36→$42
—	JP Morgan	Chris Schott	PT Raise	Overweight	$35→$40
—	B of A Securities	Jason Gerberry	PT Raise	Buy	$38→$42
—	Piper Sandler	David Amsellem	PT Raise	Overweight	$40→$41

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Indus (TEVA) Stock Price Target 2026

Latest Upgrades and Downgrades for Teva Pharmaceutical Indus Stock

Teva Pharmaceutical Indus (TEVA) Stock Price Target 2026

Latest Upgrades and Downgrades for Teva Pharmaceutical Indus Stock

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

PRO
Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

PRO
TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

PRO
Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

PRO
TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Indus (TEVA) Stock Price Target 2026

Latest Upgrades and Downgrades for Teva Pharmaceutical Indus Stock

Teva Pharmaceutical Indus (TEVA) Stock Price Target 2026

Latest Upgrades and Downgrades for Teva Pharmaceutical Indus Stock

Analyst Ratings News

PROPiper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

PROLeerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

PROTD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57

PROHC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROHC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52

People Also Watch

People Also Watch

Analyst Ratings News

PROPiper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

PROLeerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

PROTD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57

PROHC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

This GameStop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROHC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

PRO
Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

PRO
TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

PRO
HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52

PRO
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

PRO
Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52

PRO
TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

PRO
HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52